c-FLIP, a master anti-apoptotic regulator

Experimental Oncology

Volumn 34, Issue 3, 2012, Pages 176-184

  Safa, A R ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; c FLIP; Cancer; Chemotherapy; Death receptors

Indexed keywords

ALVESPIMYCIN; ANTINEOPLASTIC AGENT; BBR 3610; CASPASE 10; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CYTOKINE; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; FLICE INHIBITORY PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROCASPASE 10; PROCASPASE 8; PROTEIN BID; PROTEIN KINASE B; PROTEIN PRECURSOR; SMALL INTERFERING RNA; TANESPIMYCIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CELL; CANCER RESISTANCE; CARCINOMA CELL; CELL PROTECTION; CELL SURVIVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SPLICING DEFECT; ULTRAVIOLET RADIATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; DRUG RESISTANCE, NEOPLASM; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; HUMANS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION;

EID: 84872480731     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Cereghetti GM, Scorrano L. The many shapes of mitochondrial death. Oncogene 2006; 25: 4717-24.
2. Gogvadze V, Orrenius S. Mitochondrial regulation of apoptotic cell death. Chem Biol Interact 2006; 163: 4-14.
3. Meng XW, Lee S, Kaufmann SH. Apoptosis in the treatment of cancer: A promise kept? Curr Opin Cell Biol 2006; 18: 668-76.
4. Ferri KF, Jacotot E, Blanco J, et al. Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: Role of mitochondria and caspases. J Exp Med 2000; 192: 1081-92.
5. Liu X, Kim CN, Yang J, et al. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 1996; 86: 147-57.
6. Ren D, Tu HC, Kim H, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program.Science 2010; 330: 1390-3.
7. Danial NN, Gimenez-Cassina A, Tondera D. Homeostatic functions of BCL-2 proteins beyond apoptosis. Adv Exp Med Biol 2010; 687: 1-32.
8. Szegezdi E, MacDonald DC, Ni Chonghaile T, et al. Bcl-2 family on guard at the ER. Am J Physiol Cell Physiol 2009; 296: C941-53.
9. Lavrik IN, Krammer PH. Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 2012; 19: 36-41.
10. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: Toward clinical translation. Curr Opi Cell Biol 2010; 22: 837-44.
11. Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (c-FLIP): A novel target for cancer therapy. Curr Cancer Drug Targets 2008; 8: 37-46.
12. Li H, Zhu H, Xu CJ, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the fas pathway of apoptosis. Cell 1998; 94: 491-501.
13. He B, Lu N, Zhou Z. Cellular and nuclear degradation during apoptosis. Curr Opin Cell Biol 2009; 21: 900-12.
14. Kurokawa M, Kornbluth S. Caspases and kinases in a death grip. Cell 2009; 138: 838-54.
15. Slee, EA, Keogh SA, Martin SJ. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: A potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ 2000; 7: 556-65.
16. Safa AR, Pollok KE. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers (Basel) 2011; 3: 1639-71.
17. Micheau O. Cellular FLICE-inhibitory protein: An attractive therapeutic target? Expert Opin Ther Targets 2003; 7: 559-73.
18. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010; 42: 210-3.
19. Ueffing N, Singh KK, Christians A, et al. A single nucleotide polymorphism determines protein isoform production of the human c-FLIP protein. Blood 2009; 114: 572-9.
20. Kump E, Ji J, Wernli M, et al. Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis. Oncogene 2008; 27: 3856-64.
21. Panner A, Nakamura JL, Parsa AT, et al. mTOR-independent translational control of the extrinsic cell death pathway by RalA. Mol Cell Biol 2006; 26: 7345-57.
22. Panner A, Parsa AT, Pieper RO. Translational regulation of TRAIL sensitivity. Cell Cycle 2006, 5: 147-50.
23. Bleumink M, Köhler R, Giaisi M, et al. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-Cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ 2011; 18: 362-70.
24. Poukkula M, Kaunisto A, Hietakangas V, et al. Rapid turnover of c-FLIPshort is determined by its unique C-terminal tail. J Biol Chem 2005; 280: 27345-55.
25. L turnover. Cell 2006; 124: 601-13.
26. Kaunisto A, Kochin V, Asaok T, et al. PKC-mediated phosphorylation regulates c-FLIP ubiquitylation and stability. Cell Death Differ 2009; 16: 1215-26.
27. Jung SN, Park IJ, Kim MJ, et al. Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp Cell Res 2009; 315: 2433-41.
28. McLornan DP, Barrett HL, Cummins R, et al. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010; 16: 3442-51.
29. L is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007; 13: 5070-5.
30. Korkolopoulou P, Goudopoulou A, Voutsinas G, et al. c-FLIP expression in bladder urothelial carcinomas: Its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004; 63: 1198-204.
31. Wang W, Wang S, Song X, et al. The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis. Gynecol Oncol 2007; 105: 571-7.
32. Valnet-Rabier MB, Challier B, Thiebault S, et al. c-FLIP protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol 2005; 128: 767-73.
33. Valente G, Manfroi, F, Peracchio C, et al. cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br J Haematol 2006; 132: 560-70.
34. Li X, Pan X, Zhang H, et al. Overexpression of cFLIP in head and neck squamous cell carcinoma and its clinicopathologic correlations. J Cancer Res Clin Oncol 2008; 134: 609-15.
35. Du X, Bao G, He X, et al. Expression and biological significance of c-FLIP in human hepatocellular carcinomas. J Exp Clin Cancer Res 2009; 28: 24.
36. Zhou XD, Yu JP, Liu J, et al. Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma. Clin Sci (Lond.) 2004; 106: 397-405.
37. S as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut 2011; 60: 225-37.
38. McCourt C, Maxwell P, Mazzucchelli R, et al. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res 2012; 18: 3822-33.
39. Zhang N, Hopkins K, He YW. The long isoform of cellular FLIP is essential for T lymphocyte Proliferation through an NF-κB-independent pathway. J Immunol 2008; 180: 5506-11.
40. Yeh WC, Itie A, Elia AJ, et al. Requirement for casper (c-FLIP) in regulation of death receptor-Induced apoptosis and embryonic development. Immunity 2000; 12: 633-42.
41. Melki MT, Saïdi H, Dufour A, et al. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk - A pivotal role of HMGB1. PLoS Pathog 2010; 6: e1000862.
42. Bagnol M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signaling: A key regulator of receptor-mediated apoptosis in physiologic context and cancer. Int J Biochem Cell Biol 2010; 42: 210-3.
43. Testa U. TRAIL/TRAIL-R in hematologic malignancies. J Cell Biochem 2010; 110: 21-34.
44. Yang JK. FLIP as an anti-cancer therapeutic target. Yonsei Med J 2008: 49: 19-27.
45. Yu JW, Shi Y. FLIP and the death effector domain family. Oncogene 2008; 27: 6216-27.
46. Li FY, Jeffrey PD, Yu JW, et al. Crystal structure of a viral FLIP: Insights into FLIP-mediated inhibition of death receptor signaling. J Biol Chem 2006; 281: 2960-8.
47. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006; 6: 196-204.
48. Kim S, Lee TJ, Park JW, et al. Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells. J Cell Biochem 2008; 105: 971-9.
49. Day TW, Huang S, Safa AR. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol 2008; 76: 1694-704.
50. L to death receptor 5. J Biol Chem 2004; 279: 55594-601.
51. Chaudhary PM, Eby MT, Jasmin A, et al. Activation of the NF-κB pathway by caspase 8 and its homologs. Oncogene 2000; 19: 4451-60.
52. Fang LW, Tai TS, Yu WN, et al. Phosphatidylinositide 3-kinase priming couples c-FLIP to T cell activation. J Biol Chem 2004; 279: 13-8.
53. Dohrman A, Kataoka T, Cuenin S, et al. Cellular FLIP (long form) regulates CD8+ T cell activation through caspase-8-dependent NF-kappa B activation. J Immunol 2005; 174: 5270-8.
54. Golks A, Brenner D, Krammer PH, et al. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-κB activation. J Exp Med 2006; 203: 1295-305.
55. Iyer AK, Azad N, Talbot S, et al. Antioxidant c-FLIP inhibits Fas ligand-induced NF-κB activation in a phosphatidylinositol 3-kinase/Akt-dependent manner. J Immunol 2011; 187: 3256-66.
56. Quintavalle C, Incoronato M, Puca L, et al. c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity. Cell Death Differ 2010; 17: 1908-16.
57. Kim MJ, Kim HB, Bae JH, et al. Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway. Biochem Pharmacol 2009; 78: 573-82.
58. L. Biochem J 2004; 382: 651-7.
59. S stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 2010; 70: 5046-53.
60. S stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 2009; 69: 7911-6.
61. Kim YY, Park BJ, Seo GJ, et al. Long form of cellular FLICE-inhibitory protein interacts with daxx and prevents Fas-induced JNK activation. Biochem Biophys Res Commun 2003; 312: 426-33.
62. L, directly binds to MKK7 and inhibits the JNK pathway. EMBO J 2006; 25: 5549-59.
63. Yang BF, Xiao C, Roa WH, et al. Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells. J Biol Chem 2003; 278: 7043-50.
64. Xiao C, Yang BF, Song JH, et al. Inhibition of CaMKII-mediate c-FLIP expression sensitizes malignant melanoma cells to TRAIL-induced apoptosis. Exp Cell Res 2005; 304: 244-55.
65. Higuchi H, Yoon JH, Grambihler A, et al. Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis. J Biol Chem 2003; 278: 454-61.
66. Pawar PS, Micoli KJ, Ding H, et al. Calmodulin binding to cellular FLICE-like inhibitory protein modulates Fas-induced signalling. Biochem J 2008; 412: 459-68.
67. Jing G, Yuan K, Liang Q, et al. Reduced CaM/FLIP binding by a single point mutation in c-FLIP(L) modulates Fas-mediated apoptosis and decreases tumorigenesis. Lab Invest 2012; 92: 82-90.
68. L in proliferation and cell-cycle progression of primary hepatocytes. Carcinogenesis 2005; 26: 2086-94.
69. Stagni V, Mingardi M, Santini S, et al. ATM kinase activity modulates cFLIP protein levels: Potential interplay between DNA damage signalling and TRAIL-induced apoptosis. Carcinogenesis 2010; 31: 1956-63.
70. Naito M, Katayama R, Ishioka T, et al. Cellular FLIP inhibits β-catenin ubiquitylation and enhances Wnt signaling. Mol Cell Biol 2004; 24: 8418-27.
71. Katayama R, Ishioka T, Takada S, et al. Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L. J Cell Sci 2010; 123: 23-8.
72. Zhang L, Ren X, Alt E, et al. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 2010; 464: 1058-61.
73. Chen HX, Liu YJ, Zhou XD, et al. Expression of cellular FLICE/caspase-8 inhibitory protein is associated with malignant potential in endometrial carcinoma. Int J Gynecol Cancer 2005; 15: 663-70.
74. Wang W, Wang S, Song X, et al. The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis. Gynecol Oncol 2007; 105: 571-7.
75. Wang W, Fang Y, Sima N, et al. Triggering of death receptor apoptotic signaling by human papillomavirus 16 E2 protein in cervical cancer cell linesis mediated by interaction with c-FLIP. Apoptosis 2011; 16: 55-66.
76. Ishioka T, Katayama R, Kikuchi R, et al. Impairment of the ubiquitin-proteasome system by cellular FLIP. Genes Cells 2007; 12: 735-44.
77. Gao S, Wang H, Lee P, et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol 2006; 36: 463-83.
78. Park MA, Zhang G, Mitchell C, et al. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther 2008; 7: 2633-48.
79. S to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res 2007; 67: 9482-89.
80. Walker T, Mitchell C, Park MA, et al. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol 2009; 76: 342-55.
81. Zhang G, Park MA, Mitchell C, et al. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 2008; 14: 5385-99.
82. Mitchell C, Kabolizadeh P, Ryan J, et al. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Mol Pharmacol 2007; 72: 704-14.
83. Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011; 3: 279-96.
84. Longley DB, Wilson TR, McEwan M, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838-48.
85. Logan AE, Wilson TR, Fenning C, et al. In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide. Apoptosis 2010; 15: 1435-43.
86. Kinoshita H, Yoshikawa H, Shiiki K, et al. Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. Int J Cancer 2000; 88: 986-91.
87. Abedini MR, Muller EJ, Brun J, et al. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res 2008; 68: 4511-7.
88. Song JH, Song DK, Herlyn M, et al. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1β-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Cancer Res 2003; 9: 4255-66.
89. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005; 5: 2.
90. Chatterjee D, Schmitz I, Krueger A, et al. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIPshort. Cancer Res 2001; 61: 7148-54.
91. Yerbes R, López-Rivas A. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL. Invest New Drugs 2012; 30: 541-7.
92. Lucas DM, Alinari L, West DA, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5: e10941.
93. Bijangi-Vishehsaraei K, Saadatzadeh MR, Huang S, et al. 4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) Targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells. Mol Cell Biochem 2010; 342: 133-42.
94. Wood TE, Dalili S, Simpson CD, et al. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther 2010; 9: 246-56.
95. Schimmer AD, Thomas MP, Hurren R, et al. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res 2006; 66: 2367-75.
96. Mawji IA, Simpson CD, Gronda M, et al. A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res 2007; 67: 8307-15.
97. Kerr E, Holohan C, McLaughlin KM, et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ 2012; 19: 1317-27.